T cell compositions for immunotherapy
AssigneeGeneius Biotechnology, Inc.
InventorsAlfred E. SLANETZ, Terry Y. NAKAGAWA, Marissa A. HERRMAN
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions comprising a heterogeneous population of T cells with reactivity to selected antigens that are useful for adoptive immunotherapy and methods for making the T cell compositions.
Claims30
A method for making a composition comprising T cells, the method comprising the steps of:
- (a) obtaining an initial cell population comprising T-cells;
- (b) stimulating the T-cells by exposing the initial cell population to one or more target antigens and to cytokines resulting in a first intermediate cell population,
- (c) culturing the first intermediate cell population in media comprising cytokines resulting in a second intermediate cell population;
- (d) exposing the second intermediate cell population to tetrameric antibodies that bind CD3, CD28, and CD2 to effect polyclonal stimulation of the T-cells in the second intermediate cell population resulting in a third intermediate cell population;
- (e) testing the third intermediate cell population for antigen-specific reactivity;
- and
- (f) harvesting the resulting composition comprising T-cells to obtain a final T-cell population.
-3. (canceled)
-8. (canceled)
-11. (canceled)
-14. (canceled)
-18. (canceled)
A method for making a composition comprising T cells, the method comprising the steps of:
- (a) obtaining an initial cell population comprising T-cells;
- (b) selecting T-cells based on expression of T-cell activation markers resulting in a selected cell population,
- (c) exposing the selected cell population to tetrameric antibodies that bind CD3, CD28, and CD2 to effect polyclonal stimulation of the T-cells in the selected cell population resulting in an intermediate cell population;
- (d) polyclonal stimulation of the T-cells in the intermediate cell population, and
- (e) harvesting the resulting composition-comprising a final cell population of T-cells.
(canceled)
(canceled)
(canceled)
-32. (canceled)
-37. (canceled)
A composition comprising T-cells for immunotherapy wherein the composition comprises greater than half a million CD3+ cells, wherein the live cells comprise greater than 70% CD3+ T-cells, and wherein the T-cells are predominantly CD8+ versus CD4+ T-cells and are predominantly effector memory T-cells.
Dependencies are inferred from the claim text.